A study by researchers at the Ohio State University Comprehensive Cancer Center demonstrated that treatment of EGFR-mutated lung cancer cell lines with erlotinib, while showing robust cell death, enriches the ALDH+ cells through EGFR-dependent activation of the Notch pathway [40]. This evidence concerns the gene EGFR and lung carcinoma.